secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007054
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023
--------------------------------------------------------------------------------

- Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.
- Phase 3 KONFIDENT trial enrollment exceeds 50%; topline data expected H2 2023.
- FDA guidance: no efficacy trials required for ODT sNDA; PMDA guidance for Japan.
- Cash and securities $171.7M; $58M financing extends runway into 2025.
- Phase 2 sebetralstat data published in The Lancet; CFO Palleiko promoted to President.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/0000950170-23-007054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/kalv-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer